1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Pneumonia – Pipeline Review, H1 2013

Pneumonia – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 160 pages

Pneumonia – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Pneumonia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pneumonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pneumonia. Pneumonia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pneumonia.
- A review of the Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pneumonia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Pneumonia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pneumonia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Pneumonia - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pneumonia Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Pneumonia 9
Pneumonia Therapeutics under Development by Companies 11
Pneumonia Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Pneumonia Therapeutics - Products under Development by Companies 19
Pneumonia Therapeutics - Products under Investigation by Universities/Institutes 22
Companies Involved in Pneumonia Therapeutics Development 23
Sequella, Inc. 23
Shionogi and Co., Ltd. 24
AlphaRx, Inc. 25
AstraZeneca PLC 26
Dainippon Sumitomo Pharma Co., Ltd. 27
ACE BioSciences A/S 28
Cubist Pharmaceuticals, Inc. 29
Wockhardt Limited 30
Paratek Pharmaceuticals, Inc. 31
Basilea Pharmaceutica Ltd. 32
Oragenics, Inc. 33
Pacgen Biopharmaceuticals Corporation 34
BioCryst Pharmaceuticals, Inc. 35
Flamel Technologies S.A. 36
Dongwha Pharm Co., Ltd. 37
Theravance, Inc. 38
LTT Bio-Pharma Co., Ltd. 39
Synairgen plc 40
PolyMedix, Inc. 41
Mucosis B.V. 42
Kenta Biotech Ltd. 43
aRigen Pharmaceuticals, Inc. 44
BioStar Pharmaceuticals, Inc. 45
KaloBios Pharmaceuticals, Inc. 46
Ancora Pharmaceuticals Inc. 47
Trius Therapeutics, Inc. 48
Tetraphase Pharmaceuticals Inc. 49
TaiGen Biotechnology Co., Ltd. 50
Savara, Inc. 51
Pulmotect, Inc. 52
Durata Therapeutics Inc. 53
APEPTICO Forschung und Entwicklung GmbH 54
Pneumonia - Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Combination Products 56
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 62
dalbavancin - Drug Profile 62
vancomycin - Drug Profile 64
omadacycline tosylate - Drug Profile 65
PC-SOD - Drug Profile 68
MU-1140 - Drug Profile 70
panobacumab - Drug Profile 71
PAC-G31P - Drug Profile 73
KB-001A - Drug Profile 75
SQ-641 - Drug Profile 77
ACE-810 - Drug Profile 78
ACE-820 - Drug Profile 79
tedizolid phosphate - Drug Profile 80
zabofloxacin - Drug Profile 82
nemonoxacin - Drug Profile 84
nemonoxacin - Drug Profile 86
CXA-201 + [levofloxacin] - Drug Profile 88
faropenem medoxomil - Drug Profile 90
PneuGEM Vaccine - Drug Profile 92
Heptavalent Pneumococcal Conjugate Vaccine - Drug Profile 93
interferon beta - Drug Profile 94
rituximab - Drug Profile 96
doripenem - Drug Profile 98
MAR Program - Drug Profile 100
telavancin hydrochloride - Drug Profile 101
eravacycline - Drug Profile 103
ceftobiprole medocaril - Drug Profile 104
simvastatin - Drug Profile 106
colistin - Drug Profile 107
AP-301 - Drug Profile 108
Second Generation Ketolides - Drug Profile 110
vancomycin hydrochloride - Drug Profile 111
eptifibatide + iloprost - Drug Profile 113
SynGEM - Drug Profile 115
tigecycline - Drug Profile 116
doxycycline - Drug Profile 118
Vaccine For Pseudomonas - Drug Profile 119
MVX-507 - Drug Profile 120
MVX-504 - Drug Profile 121
MVX-505 - Drug Profile 123
SM-295291 - Drug Profile 124
SM-369926 - Drug Profile 125
BCX-2798 - Drug Profile 126
BCX-2855 - Drug Profile 127
Flagellin Fusion Protein Vaccine For Pneumococcal pneumonia - Drug Profile 128
Pneumonia Therapeutics - Drug Profile Updates 129
Pneumonia Therapeutics - Discontinued Products 146
Pneumonia Therapeutics - Dormant Products 147
Pneumonia - Product Development Milestones 149
Featured News and Press Releases 149
Appendix 156
Methodology 156
Coverage 156
Secondary Research 156
Primary Research 156
Expert Panel Validation 156
Contact Us 157
Disclaimer 157



List of Tables

Number of Products Under Development for Pneumonia, H1 2013 12
Products under Development for Pneumonia - Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2013 17
Comparative Analysis by Late Stage Development, H1 2013 18
Comparative Analysis by Mid Clinical Stage Development, H1 2013 19
Comparative Analysis by Early Clinical Stage Development, H1 2013 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 21
Products under Development by Companies, H1 2013 22
Products under Development by Companies, H1 2013 (Contd..1) 23
Products under Development by Companies, H1 2013 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2013 25
Sequella, Inc., H1 2013 26
Shionogi and Co., Ltd., H1 2013 27
AlphaRx, Inc., H1 2013 28
AstraZeneca PLC, H1 2013 29
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 30
ACE BioSciences A/S, H1 2013 31
Cubist Pharmaceuticals, Inc., H1 2013 32
Wockhardt Limited, H1 2013 33
Paratek Pharmaceuticals, Inc., H1 2013 34
Basilea Pharmaceutica Ltd., H1 2013 35
Oragenics, Inc., H1 2013 36
Pacgen Biopharmaceuticals Corporation, H1 2013 37
BioCryst Pharmaceuticals, Inc., H1 2013 38
Flamel Technologies S.A., H1 2013 39
Dongwha Pharm Co., Ltd., H1 2013 40
Theravance, Inc., H1 2013 41
LTT Bio-Pharma Co., Ltd., H1 2013 42
Synairgen plc, H1 2013 43
PolyMedix, Inc., H1 2013 44
Mucosis B.V., H1 2013 45
Kenta Biotech Ltd., H1 2013 46
aRigen Pharmaceuticals, Inc., H1 2013 47
BioStar Pharmaceuticals, Inc., H1 2013 48
KaloBios Pharmaceuticals, Inc., H1 2013 49
Ancora Pharmaceuticals Inc., H1 2013 50
Trius Therapeutics, Inc., H1 2013 51
Tetraphase Pharmaceuticals Inc., H1 2013 52
TaiGen Biotechnology Co., Ltd., H1 2013 53
Savara, Inc., H1 2013 54
Pulmotect, Inc., H1 2013 55
Durata Therapeutics Inc., H1 2013 56
APEPTICO Forschung und Entwicklung GmbH, H1 2013 57
Assessment by Monotherapy Products, H1 2013 58
Assessment by Combination Products, H1 2013 59
Assessment by Stage and Route of Administration, H1 2013 61
Assessment by Stage and Molecule Type, H1 2013 64
Pneumonia Therapeutics - Drug Profile Updates 132
Pneumonia Therapeutics - Discontinued Products 149
Pneumonia Therapeutics - Dormant Products 150
Pneumonia Therapeutics - Dormant Products (Contd..1) 151



List of Figures

Number of Products under Development for Pneumonia, H1 2013 12
Products under Development for Pneumonia - Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 17
Late Stage Products, H1 2013 18
Mid Clinical Stage Products, H1 2013 19
Early Clinical Stage Products, H1 2013 20
Discovery and Pre-Clinical Stage Products, H1 2013 21
Assessment by Monotherapy Products, H1 2013 58
Assessment by Combination Products, H1 2013 59
Assessment by Route of Administration, H1 2013 60
Assessment by Stage and Route of Administration, H1 2013 61
Assessment by Molecule Type, H1 2013 62
Assessment by Stage and Molecule Type, H1 2013 63

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

2017 World Infectious Disease Testing Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales and Volume Forecasts for 100 Microbiology Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies, Opportunities

  • $ 59500
  • Industry report
  • January 2017
  • by Venture Planning Group

This unique 68-country survey from VPGMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well ...

2017 World Blood Typing, Grouping and Infectious Disease Screening Market: North America, Europe, Asia-Pacific, LATAM, Middle East--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

2017 World Blood Typing, Grouping and Infectious Disease Screening Market: North America, Europe, Asia-Pacific, LATAM, Middle East--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

  • $ 43500
  • Industry report
  • January 2017
  • by Venture Planning Group

This comprehensive 68-country report from VPGMarketResearch.com provides granular data and analysis not available from any other source. The report is designed to help current suppliers and potential market ...

2017 World Transfusion Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Middle East--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

2017 World Transfusion Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Middle East--Volume and Sales Forecasts for 40 Tests, Supplier Shares, Competitive Strategies, Instrumentation, Technologies

  • $ 43500
  • Industry report
  • January 2017
  • by Venture Planning Group

This comprehensive 68-country report from VPGMarketResearch.com provides granular data and analysis not available from any other source. The report is designed to help current suppliers and potential market ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.